Major job opportunity: Director, BARDA Division of Research, Innovation, and Ventures (DRIVe). Deadline 7 Dec 2019

Dear All: BARDA’s Division for Research, Innovation and Ventures (DRIVe) was established earlier this year with a mission to develop countermeasures to protect Americans from natural and intentional health security threats. 

BARDA now seeks a permanent director for the Division. The job description for this role is that the Director will:

  • Use vision and strategic and scientific leadership to create programs that transform medical countermeasures and how they are made and used.
  • Pursue imaginative and innovative research and development projects with the potential to have a significant positive impact on national health care challenges and meet live-saving national security needs.
  • Identify promising MCMs and technology investment priorities and advance research and development strategies through public and private partnerships and collaborations with governmental and non-governmental organizations and other funding partners.
  • Communicate programmatic priorities, funding opportunities and models, and business practices to diverse audiences that include industry, governmental and non-governmental organizations, funding partners, and the general public.
  • Identify new business practices and funding mechanisms to increase efficiency and effectiveness in meeting programmatic objectives.
  • Organize, direct, and manage all human, financial, and informational resources to implement a comprehensive strategy that delivers effective high quality programs.

Could this be you? The deadline for applications (https://www.usajobs.gov/GetJob/ViewDetails/515065900) is 7 Dec 2019.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

  • 29-30 Nov 2018 (Birmingham, UK): BSAC (British Society Antimicrobial Chemotherapy): Antibiotic Resistance Mechanisms Workshop for Researchers
  • 7 Dec 2018 (Boston, MA): BAARN, Boston Area Antimicrobial Resistance Network 2018 symposium, 8:30am to 7pm at The Starr Center (185 Cambridge Street, Boston, MA). This is an excellent networking opportunity, especially for those based in the Boston area. Register here.
  • [NEW] 17 Dec 2018 (online): Webinar on TDM of antibiotics, sponsored by the journal Clinical Mass Spectroscopy.
  • [NEW] 13 Dec 2018 (online): CDD webinar entitled “New Strategies in Antibiotic Drug Development.” Register here.
  • 15 Jan 2018 (London): BSAC’s Antimicrobial Chemotherapy Conference 2019: “An ABC for everyone involved in developing new antimicrobials.” Details here.
  • [NEW] 4-5 Feb 2019 (London): Hamied Foundation UK-India Antimicrobial Resistance Meeting 2019. This is a 2-day meeting focused on building research links between the UK and India with the specific aim of jointly addressing the challenge of AMR. Register here.
  • 14-15 Mar 2019 (Berlin): BEAM-, CARB-X-, and ND4BB-ENABLE-sponsored Berlin Conference on Novel Antimicrobials and AMR Diagnostics. Details here.
  • 21-22 Mar 2019 (Birmingham, UK): BSAC Spring Conference.
  • [NEW] 26 Mar 2019 (London, UK): Sponsored by The Economist, a 1-day symposium entitled “Antimicrobial Resistance: Preventing an antibiotic apocalypse.” Register here.
  • [NEW] 13-16 Apr 2019 (Amsterdam): Annual ECCMID meeting.
  • [NEW] 24-26 Apr 2019 (Boston). Annual SHEA (Soc. for Hospital Epidemiology of America) Spring meeting
  • [NEW] 3-6 Jun 2019 (Philadelphia): Annual BIO meeting
  • [NEW] 20-24 June 2019 (San Francisco): Annual ASM Microbe meeting.
  • [NEW — mark your calendar now!] 3-6 Sep 2019 (Boston). Annual ASM-ESCMID Conference on Antibiotic Development. The Bootcamp series will continue on 3 Sep with the main meeting on 4-6 Sep. Mark your calendar now and check back here for details.
  • [NEW] 6-8 Sep 2019 (Bilbao, Spain): 5th ESCMID conference on Vaccines. Check back here for details.
  • [NEW] 2-6 Oct 2018 (Washington, DC): IDSA’s annual IDWeek meeting.
  • 19-27 Oct 2019 (Annecy, France): International Course on Antibiotics and Resistance (ICARe) – A soup-to-nuts intensive residential training program on all things AMR, especially R&D for new antibiotics. See this link for details.

Share

ENABLE-2 funding now includes Hit Identification & Validation

Dear All, I wrote on 25 Aug 2023 about the ENABLE-2 program and its support for hit-to-lead compound development. As a reminder, that program is focused on molecules with the potential to be direct-acting therapies for one or more of the following priority pathogens: ESBL-producing/carbapenem-resistant Enterobacteriaceae (E. coli, K. pneumoniae), P. aeruginosa, A. baumannii, methicillin-resistant S. aureus, or vancomycin-resistant E. faecium. Adding to that program, there is now an ENABLE-2

NIAID/DMID thinking for FY2026: Antibacterials, Phage, and Antifungals

Dear All, NIAID’s DMID (Division of Microbiology and Infectious Diseases) recently held a council meeting during which they proposed program concepts that encompassed both antibacterial therapies (including phage) as well as antifungal therapies for funding in FY 2026 (the year that would run from 1 Oct 2025 to 30 Sep 2026). There is no guarantee that

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Dear All, WHO have released an update through 31 Dec 2023 of their ongoing series of antibacterial pipeline reviews! Here are the links you need: The report: 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis and a press release about the report. Infographics: Key facts and recommendations from the 2023 antibacterial agents in clinical

The (confusing!) language of AMR: ChatGPT tries to help!

Dear All (Wonkish alert! Not technical but lengthy … so settle in and enjoy the ride!): Regular readers will know of my fascination with language: e.g., this 20 Feb 2020 newsletter entitled “Language Matters: CRE vs. CPE; SDD vs. I; And MDR, XDR, PDR, UDR vs. DTR.” How about that for acronymics taken to Olympian

Scroll to Top